For people with atrial fibrillation (Afib), investigational abelacimab proved to be a potent dual factor XI/XIa inhibitor with much lower safety risks compared with a direct oral anticoagulant (DOAC), ...

Clinically significant reductions in bleeding underscore abelacimab’s strong potential to address an unmet need for patients ...

Researchers evaluated a drug that represents a new class of anticoagulants known as Factor XI inhibitors for treating patients with atrial fibrillation as part of the AZALEA-TIMI 71 Study. The trial ...

Patients with atrial fibrillation are typically prescribed an anticoagulant, or blood thinner, to reduce the risk of stroke, but many may discontinue them or never receive a prescription due to ...

Atrial fibrillation (AF) is the most common cardiac arrhythmia and predisposes patients to stroke and systemic embolism. Vitamin K antagonists have been the only available oral anticoagulants for ...

Among patients with atrial fibrillation, there is an unmet need for effective anticoagulation that prevents stroke but incurs a lower risk of bleeding than direct-acting oral anticoagulants.

Patients with atrial fibrillation are typically prescribed an anticoagulant, or blood thinner, to reduce the risk of stroke, but many may discontinue them or never receive a prescription due to ...

"Oral anticoagulant therapy has important limitations ... closure "is a safe and effective first-line option for atrial fibrillation ablation patients. It has similar thromboembolic protection ...

Patients with atrial fibrillation are typically prescribed an anticoagulant, or blood thinner, to reduce the risk of stroke, but many may discontinue ...

Boston Scientific Corp. reported positive data for two key atrial fibrillation therapies at AF Symposium 2025 on January 17.